5 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 2.9% per year over the past 4 years.
Net income has grown faster than revenue (10.7% vs 2.9% per year).
Operating margin has expanded, at 10.7% in the latest year.
Free cash flow has grown 2.9% per year over the past 4 years.
Financial health
Total debt ($113M) exceeds cash ($23M); net debt is $90M.
Total debt has grown slower than revenue (-13.6% vs 2.9% per year).
Operating income covered interest expense 5.3× in the latest year, up from 4.9× 4 years ago.
Total debt is 1.6× EBITDA.
Shareholder returns
Dividends have been paid for 5 consecutive years, consuming 6.3% of earnings and 7.2% of free cash flow.
The dividend has grown 0.5% per year over the past 4 years.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
2025
$527M
$30M
20.7%
10.7%
11.2%
5.1%
$26M
$113M
$23M
2024
$524M
$31M
19.7%
11.2%
12.7%
5.4%
$45M
$128M
$19M
2023
$510M
$37M
21.5%
10.7%
16.3%
6.3%
$14M
$166M
$15M
2022
$490M
$19M
19.6%
8.5%
10.6%
3.4%
$15M
$175M
$15M
2021
$470M
$20M
0.0%
9.6%
—
3.4%
$23M
—
—
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
Sep '26
$132M
$5M
20.4%
9.1%
2.0%
0.9%
$2M
$115M
$21M
Jun '26
$125M
$6M
18.6%
7.3%
2.2%
1.0%
$3M
$116M
$23M
Mar '26
$122M
-$789000
16.2%
1.5%
-0.3%
-0.1%
$517000
$117M
$23M
Dec '25
$138M
$5M
20.8%
11.5%
1.9%
0.8%
$5M
$113M
$23M
Sep '25
$135M
$14M
22.0%
15.6%
5.2%
2.4%
$6M
$117M
$26M
Jun '25
$130M
$11M
20.3%
11.7%
4.1%
1.8%
$10M
$126M
$31M
Mar '25
$124M
-$154000
19.5%
3.6%
-0.1%
-0.0%
$4M
$126M
$22M
Dec '24
$129M
$7M
17.8%
11.0%
3.0%
1.3%
$17M
$128M
$19M
Sep '24
$134M
$12M
20.5%
14.7%
4.7%
2.0%
$10M
$142M
$21M
Jun '24
$131M
$9M
21.2%
12.3%
3.8%
1.5%
$14M
$150M
$18M
Mar '24
$130M
$3M
19.3%
6.6%
1.4%
0.5%
$2M
$163M
$15M
Dec '23
$128M
$2M
0.0%
11.4%
1.0%
0.4%
$17M
$166M
$15M
Sep '23
$125M
$9M
0.0%
11.7%
4.1%
1.6%
-$4M
$181M
$17M
Jun '23
$128M
$23M
0.0%
14.8%
10.6%
3.8%
$7M
$185M
$26M
Mar '23
$128M
$2M
0.0%
5.0%
—
0.4%
-$5M
—
—
Dec '22
$128M
$7M
0.0%
12.2%
3.7%
1.2%
$11M
$175M
$15M
Sep '22
$126M
$8M
0.0%
11.6%
—
1.3%
$3M
—
—
Jun '22
$121M
$7M
0.0%
9.6%
—
1.2%
—
—
—
Valuation over time
How the market has priced CLB against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 51.9× (Mar '23) to 15.8× (Nov '26).
The price-to-sales ratio has fallen from 2.1× (Mar '23) to 0.9× (Nov '26).
The dividend yield has risen from 0.2% (Mar '23) to 0.4% (Nov '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Dividend yield (%)
Dividend yield %
Frequently asked questions
Is CLB growing its revenue and profit?
Over the past 4 years, Core Laboratories Inc. /De/'s revenue has grown 2.9% per year, and net income grown 10.7% per year. These are computed facts, not advice.
How much debt does CLB have?
As of FY2025, Core Laboratories Inc. /De/ reported $113M of total debt against $23M of cash; operating income covered interest expense 5.3×.
What is CLB's profit margin?
In FY2025, gross margin was 20.7%, operating margin 10.7%, and net margin 5.6%.
What is CLB's P/E ratio?
Core Laboratories Inc. /De/'s P/E (TTM) is 30.06 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the CLB stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 15.8× as of Nov '26) can differ. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.